BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating

Vera Therapeutics, Inc. (NASDAQ:VERA) is one of the best small cap stocks with the highest upside. BofA initiated coverage of Vera Therapeutics, Inc. (NASDAQ:VERA) with a Buy rating and a $48 price target on October 16.

The firm told investors that it sees potential upside in the company’s shares because of its lead drug, atacicept, a novel biologic investigational therapeutic launching into a multibillion-dollar market.

The firm also stated that its $3 billion nominal peak sales estimation for 2037 shows atacicept’s potential as a favorable treatment option in several autoimmune disorders, pending future clinical data validation.

Vera Therapeutics, Inc. (NASDAQ:VERA) is a clinical-stage biotechnical company that develops  and commercializes transformative treatments for immunological diseases.

While we acknowledge the potential of VERA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VERA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.